Enimmune Corporation

Enimmune Corporation is a biotechnology company specializing in research, development, and marketing within the healthcare sector. Founded in 2014 and headquartered in Taiwan, Enimmune focuses primarily on creating novel pharmaceutical products targeting infectious diseases. Its portfolio includes biological agents, monoclonal antibodies, vaccines, and small molecule drugs, with notable products such as the Tuberculin PPD for tuberculosis testing and the Enterovirus 71 vaccine. Enimmune also engages in the trade and distribution of vaccines and diagnostic reagents, serving both domestic and select international markets. The company plays a vital role in addressing public health challenges by advancing preventative solutions for diseases like enterovirus, pneumonia, norovirus, dengue fever, and coronaviruses. Through strategic collaborations and exclusive distribution agreements, Enimmune supports innovation and strengthens Taiwan’s biopharmaceutical industry, contributing to the broader sector of medical research and technology development.